Release Details

LivaNova PLC files amendment to transitional Form 10Q for the period July 25, 2015 to October 18, 2015

December 8, 2015

8 December 2015


LivaNova PLC (the “Company” or “LivaNova”) today announced that it filed Amendment No. 1 to the Quarterly Report on Form 10-Q under the U.S. Securities Exchange Act of 1934, as amended, for LivaNova’s predecessor company, Cyberonics, Inc., for the transitional period July 25, 2015 to October 18, 2015 (“Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”) on 8 December 2015. The Form 10-Q can be found on the SEC’s website at and in the Investor Relations section of the Company’s website at

A copy of the Form 10-Q has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at

- End -

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit, or contact:


Investor Relations:
Vivid Sehgal
Chief Financial Officer


Investor Relations and Media:
Greg Browne
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332